{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:52Z","timestamp":1792451752910,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.labinv.2026.106150","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:28:00Z","timestamp":1782257280000},"page":"106150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Artificial Intelligence (AI)\u2013Assisted Human Epidermal Growth Factor Receptor 2 (HER2) Scoring in Breast Cancer: Diagnostic Agreement and Understanding Discordance"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-571X","authenticated-orcid":false,"given":"Frederik","family":"Deman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Rasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Broeckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Siozopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Vibeke","family":"L\u00e6nkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A.","family":"Torres-Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"\u00c1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Dendooven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.labinv.2026.106150_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","article-title":"Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study","volume":"16","author":"Hennigs","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.labinv.2026.106150_bib2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2026.106150_bib3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.labinv.2026.106150_bib4","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2026.106150_bib5","first-page":"993","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update","volume":"147","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2026.106150_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2026.106150_bib7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2026.106150_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100925","article-title":"International expert consensus recommendations for HER2 reporting in breast cancer: focus on HER2-low and ultralow categories","volume":"39","author":"Rakha","year":"2026","journal-title":"Mod Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1309\/6ANB-QXCF-EHKC-7UC7","article-title":"Interobserver reproducibility of Her-2\/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest","volume":"118","author":"Hsu","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/172460080401900210","article-title":"Interobserver reproducibility of immunohistochemical Her-2\/Neu evaluation in human breast cancer: the real-world experience","volume":"19","year":"2004","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.labinv.2026.106150_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low ERBB2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.labinv.2026.106150_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100944","article-title":"Agreement across 10 artificial intelligence models in assessing human epidermal growth factor receptor 2 (HER2) expression in breast cancer whole-slide images","volume":"39","author":"McKelvey","year":"2026","journal-title":"Mod Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41746-025-01483-8","article-title":"Systematic review and meta-analysis of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry","volume":"8","author":"Albuquerque","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.labinv.2026.106150_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155472","article-title":"Artificial intelligence for assisted HER2 immunohistochemistry evaluation of breast cancer: a systematic review and meta-analysis","volume":"260","author":"Wu","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.labinv.2026.106150_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100054","article-title":"The role of artificial intelligence in accurate interpretation of HER2 immunohistochemical scores 0 and 1+ in breast cancer","volume":"36","author":"Wu","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1186\/s12885-024-12980-6","article-title":"Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast cancer","volume":"24","author":"Xiong","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.labinv.2026.106150_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00428-021-03154-x","article-title":"Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study","volume":"479","author":"Yue","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.labinv.2026.106150_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1037\/0033-2909.88.2.322","article-title":"Integration and generalization of kappas for multiple raters","volume":"88","author":"Conger","year":"1980","journal-title":"Psychol Bull"},{"key":"10.1016\/j.labinv.2026.106150_bib19","series-title":"irrCAC: Computing Chance-Corrected Agreement Coefficients (CAC)","author":"Kilem","year":"2019"},{"key":"10.1016\/j.labinv.2026.106150_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.labinv.2026.106150_bib20","series-title":"glmtoolbox: Set of Tools to Data Analysis Using Generalized Linear Models","author":"Vanegas","year":"2024"},{"key":"10.1016\/j.labinv.2026.106150_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5858\/arpa.2013-0566-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.labinv.2026.106150_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low\u2013expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.breast.2023.06.005","article-title":"Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland \u2013 on behalf of the UK national coordinating committee for breast pathology","volume":"70","author":"Zaakouk","year":"2023","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.labinv.2026.106150_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","author":"Robbins","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib26","first-page":"815","article-title":"Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer","volume":"77","author":"Turashvili","year":"2024","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/his.15117","article-title":"Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines","volume":"84","author":"Tan","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.labinv.2026.106150_bib28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.labinv.2026.106150_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-13957-9_1","article-title":"The pre-analytical phase in surgical pathology","volume":"199","author":"Bussolati","year":"2015","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.labinv.2026.106150_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13058-023-01739-9","article-title":"High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients","volume":"25","author":"Nielsen","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.labinv.2026.106150_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.labinv.2026.106150_bib32","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/jamia\/ocac103","article-title":"Impact of artificial intelligence on pathologists\u2019 decision: an experiment","volume":"29","author":"Meyer","year":"2022","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"10.1016\/j.labinv.2026.106150_bib33","article-title":"Unbiased artificial intelligence: addressing bias in computational pathology","volume":"3","author":"Montezuma","year":"2025","journal-title":"Mayo Clin Proc Digit Health"},{"key":"10.1016\/j.labinv.2026.106150_bib34","series-title":"Bildverarbeitung f\u00fcr die Medizin 2025","first-page":"129","article-title":"Automation bias in AI-assisted medical decision-making under time pressure in computational pathology","author":"Rosbach","year":"2025"},{"key":"10.1016\/j.labinv.2026.106150_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70051","article-title":"Inter-rater agreement of HER2-low scores between expert breast pathologists and the Visiopharm digital image analysis application (HER2 APP, CE2797)","volume":"11","author":"Parry","year":"2025","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.labinv.2026.106150_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61957-9","article-title":"HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer","volume":"14","author":"Kapil","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.labinv.2026.106150_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpi.2025.100513","article-title":"Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence","volume":"19","author":"Aidt","year":"2025","journal-title":"J Pathol Inform"},{"key":"10.1016\/j.labinv.2026.106150_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13058-016-0725-1","article-title":"Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification","volume":"18","author":"Allott","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.labinv.2026.106150_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jamcollsurg.2012.09.007","article-title":"Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?","volume":"216","author":"Greer","year":"2013","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.labinv.2026.106150_bib40","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ajpath.2013.08.002","article-title":"Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine","volume":"183","author":"Rivenbark","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2024.152288","article-title":"Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry","volume":"70","author":"Wang","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.labinv.2026.106150_bib42","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/cancers16051062","article-title":"High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in early-stage and locally advanced HER2-positive breast cancer","volume":"16","author":"Tanei","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.labinv.2026.106150_bib43","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00428-025-04310-3","article-title":"HER2 intratumoral heterogeneity predicts response to neoadjuvant therapy in HER2-positive breast cancer: impact and interplay with HER3 expression","volume":"488","author":"Santoro","year":"2025","journal-title":"Virchows Arch"},{"key":"10.1016\/j.labinv.2026.106150_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/his.14877","article-title":"Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2-low breast cancer","volume":"82","author":"Sode","year":"2023","journal-title":"Histopathology"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:14:25Z","timestamp":1790378065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683726000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0023683726000802"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106150","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial Intelligence (AI)\u2013Assisted Human Epidermal Growth Factor Receptor 2 (HER2) Scoring in Breast Cancer: Diagnostic Agreement and Understanding Discordance","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106150"}}